Protocol Name |
Target Population |
Status |
|---|---|---|
GenMab 407 - F + C + HuMax (UCSD 061019) |
For more information contact Vineeta Prasad at vprasad@ucsd.edu or (858) 822-0337 | Open |
ABT-263 - (UCSD 070581) |
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia. For more information contact Vineeta Prasad at vprasad@ucsd.edu or (858) 822-0337 | Open |
| Intranodal Gene Therapy | A Phase II Study of repeat intranodal injections of Adenovirus-CD154 (Ad-ISF35) in patients with CLL who have failed chemotherapy or have foregone chemotherapy participate in a new clinical trial for a CLL vaccine. For more information contact Denise Darrah at (858) 822-5375 | Open |
| Flavopiridol | A study done with Sanofi-Aventis using a novel synthetic flavone that inhibits kinases involved in cell transcription. This study will look at safety, pharmacokinetics and efficacy of flavopiridol. For more information contact Vineeta Prasad at vprasad@ucsd.edu or (858) 822-0337 | Open |
| Revlimid + Rituximab CRC014 | Patients not wishing to undergo chemotherapy, the BCRF along with the CLL Research Consortium, have developed a front-line therapy using the well researched rituximab with Revlimid. (Phase II). For more information contact Jamie Gould at jngould@ucsd.edu | Open |
OFAR CRC012 |
Phase I/II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients with Richter's Transformation, Prolymphocytic Leukimia or Refractory /Relpsed B-Cell Chronic Lymphocytic Leukemia. For more information contact Jamie Gould at jngould@ucsd.edu | Open |
|
For a complete list of clinical trials for CLL at UCSD please consult the UCSD Cancer Center Website at: Make sure to enter "CLL" in the search window to narrow your results |
||
| CRC000 - Tissue Core (non-therapeutic) | This Study Sample Collection. The CRC tissue core study is one of the world's, if not the worlds, largest repositories of CLL materials. The collection of samples from patients around the world enable researchers to uncover CLL's mechanisms of action, with the hopeful result of developing curative stategies for patient with CLL. For more information contact Laura Rassenti at lrassenti@ucsd.edu or (858) 822-5989 | Open |